CSI Market
Sign In | Register

Immunocore Holdings Plc (IMCR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IMCR quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Immunocore Holdings Plc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-35.51
Depreciation & amortization3.27
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation37.70
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized2.22
Depreciation Rightofuse Assets-
Gross Gains On Disposals Of Equity Method Investments-
Gains Arising From Derecognition Of Financial Assets Measured At Amortised Cost-
Adjustments Remeasurement Of Right Of Use Assets-
Adjustments For Finance Income Cost-
Adjustments For Provisions-
Adjustments For Sharebased Payments-
Income Tax Expense Continuing Operations-
Adjustments For Increase Decrease In Trade Account Payable-
Adjustments For Increase Decrease In Other Liabilities-
Operating Lease Right Of Use Asset Amortization Expense2.35
Increase Decrease In Contract With Customer Liability-19.73
Increase Decrease In Operating Lease Liability-
Income taxes14.79
Purchase Of Intangible Assets Classified As Investing Activities0.00
Increase (Decrease) in Accounts Receivable7.34
Increase (Decrease) in Accounts Payable-2.46
Increase (Decrease) in Accrued Liabilities15.89
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets6.74
Other Working Capital6.18
Other Noncash Income (Expense)-2.11
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.48
Discontinued operations0.00
Net Cash flow from Operating Activities-10.71
Investing Activities
Capital Expenditures4.34
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities18.00
Payments to Acquire Marketable Securities30.00
Real Estate Investments0.00
Proceeds From Sales Of Investments Accounted For Using Equity Method-
Proceeds From Other Longterm Assets Classified As Investing Activities-
Other Inflows Outflows Of Cash Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-16.34
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-445.67
Proceeds From Issue Of Ordinary Shares-
Payments For Share Issue Costs-
Increase Decrease In Cash And Cash Equivalents-
Proceeds From Interest Bearing Loans Received Non Current-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents455.73
Interest Received Paid Excluding Capitalized Interest Operating Activities-10.06
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities12.37
Effect of exchange rate on cash flow26.66
Discontinued operations0.00
Free Cash Flow-6.37
Total Cash Flow-14.68
4 historic quarters locked

Sign in to unlock the full Immunocore Holdings Plc cash flow history.

Sign In Create Free Account

About Immunocore Holdings Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: imcr-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001671927-26-000005

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License